Skip to main content

Advertisement

SpringerLink
Log in

Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

A role for the EGF system, in particular HER1 and 2, in growth of the endometrium has been suggested but HER1 and 2 have not been studied in all locations of endometriosis and in ovarian endometrioid adenocarcinoma (OEC) which is a rare form of malignant transformation of endometriosis. Immunohistochemistry (IHC) was used for studying HER1 and HER2 in ovarian (n = 10), peritoneal (n = 10), colorectal endometriosis (n = 20) and OEC (n = 10). Fluorescent in situ hybridisation (FISH) was used for analysing the status of HER2 gene in colorectal endometriosis and OEC. All samples were negative for HER2 in both glandular and stromal cells and in glandular cells for HER1 by IHC. In 15 out of 20 colorectal endometriosis, there was a weak expression in stromal cells. Following FISH, two colorectal samples had a partial 17 aneusomy and three OEC, a 17 polysomy. The other samples were 17 disomic without HER2 amplification; HER1 and 2 do not seem to have a role in endometriosis physiopathology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Casalini P, Iorio MV, Galmozzi E et al (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200:343–350

    Article  PubMed  CAS  Google Scholar 

  2. Bhargava R, Gerald WL, Li AR et al (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18:1027–1033

    Article  PubMed  CAS  Google Scholar 

  3. Pérez-Soler R (2004) HER1/EGFR targeting: refining the strategy. Oncologist 9:58–67

    Article  PubMed  Google Scholar 

  4. Brumm C, Rivière A, Wilckens C et al (1990) Immunohistochemical investigation and northern blot analysis of c-erB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. Virchows Arch A Pathol Anat Histopathol 417:477–484

    Article  PubMed  CAS  Google Scholar 

  5. Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953–962

    PubMed  CAS  Google Scholar 

  6. Wang DP, Fujii S, Konishi I et al (1992) Expression of c-erbB-2 protein and epidermal growth factor receptor in normal tissues of the female genital tract and in the placenta. Virchows Arch A Pathol Anat Histopathol 420:385–393

    Article  PubMed  CAS  Google Scholar 

  7. Ejskjaer K, Sørensen BS, Poulsen SS et al (2005) Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Mol Hum Reprod 11:543–551

    Article  PubMed  CAS  Google Scholar 

  8. Niikura H, Sasano H, Kaga K et al (1996) Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum Pathol 27:282–289

    Article  PubMed  CAS  Google Scholar 

  9. Ejskjaer K, Sørensen BS, Poulsen SS et al (2007) Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol 104:158–167

    Article  PubMed  CAS  Google Scholar 

  10. Stovall DW, Bowser LM, Archer DF et al (1997) Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain. Fertil Steril 68:13–18

    Article  PubMed  CAS  Google Scholar 

  11. Vercellini P, Trespidi L, De Giorgi O et al (1996) Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril 65:299–304

    PubMed  CAS  Google Scholar 

  12. Jenkins S, Olive DL, Haney AF (1986) Endometriosis: pathogenetic implications of the anatomic distribution. Obstet Gynecol 67:335–338

    PubMed  CAS  Google Scholar 

  13. Dubernard G, Piketty M, Rouzier R et al (2006) Quality of life after laparoscopic colorectal resection for endometriosis. Hum Reprod 21:1243–1247

    Article  PubMed  Google Scholar 

  14. Vigano P, Somigliana E, Chiodo I et al (2006) Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Human Reprod Update 12:77–89

    Article  CAS  Google Scholar 

  15. Hsieh YY, Chang CC, Tsai FJ et al (2005) T homozygote, allele of epidermal growth factor receptor 2073 gene polymorphism are associated with higher susceptibility to endometriosis and leiomyomas. Fertil Steril 83:796–799

    Article  PubMed  CAS  Google Scholar 

  16. Melega C, Balducci M, Bulletti C et al (1991) Tissue factors influencing growth and maintenance of endometriosis. Ann N Y Acad Sci 622:256–265

    Article  PubMed  CAS  Google Scholar 

  17. Nasu K, Hayata T, Takai N et al (1995) Immunohistochemical study of c-erb B-2 protein expression in endometriosis. Hum Reprod 10:935–937

    PubMed  CAS  Google Scholar 

  18. Schneider J, Jimenez E, Rodriguez F et al (1998) c-myc, c-erb-B2, nm23 and p53 expression in human endometriosis. Oncol Rep 5:49–52

    PubMed  CAS  Google Scholar 

  19. Marwah N, Bansal C, Gupta S et al (2007) Immunohistochemical study of the expression of HER-2/neu oncogene in ovarian lesions. Indian J Pathol Microbiol 50:489–492

    PubMed  Google Scholar 

  20. Berek JS, Schultes BC, Nicodemus CF (2003) Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21:168–174

    Article  Google Scholar 

  21. Malamou-Mitsi V, Crikoni O, Timotheadou E (2007) Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res 27:1157–1165

    PubMed  CAS  Google Scholar 

  22. Sasaki N, Kudoh K, Kita T et al (2007) Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma. J Obstet Gynaecol Res 33:17–23

    Article  PubMed  CAS  Google Scholar 

  23. Tubbs RR, Pettay JD, Roche PC et al (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19:2714–2721

    PubMed  CAS  Google Scholar 

  24. Gong Y, Yan K, Lin F et al (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8:203–211

    Article  PubMed  CAS  Google Scholar 

  25. Inagaki M, Yoshida S, Kennedy S et al (2007) Association study between epidermal growth factor receptor and epidermal growth factor polymorphisms and endometriosis in a Japanese population. Gynecol Endocrinol 24:1–5

    Google Scholar 

  26. Tuefferd M, Couturier J, Penault-Llorca F et al (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2:1138

    Article  CAS  Google Scholar 

  27. Noack F, Schmidt H, Buchweitz O (2004) Genomic imbalance and onco-protein expression of ovarian endometrioid adenocarcinoma arisen in an endometriotic cyst. Anticancer Res 24:151–154

    PubMed  CAS  Google Scholar 

  28. Bunn PA Jr, Dziadziuszko R, Varella-Garcia M et al (2006) Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 12:3652–3656

    Article  PubMed  CAS  Google Scholar 

  29. Li AR, Chitale D, Riely GJ et al (1995) Immunohistochemical study of c-erb B-2 protein expression in endometriosis. Hum Reprod 10:935–937

    Google Scholar 

  30. Ladanyi M (2008) EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10:242–248

    Article  PubMed  CAS  Google Scholar 

  31. Ichihara S, Toyooka S, Fujiwara Y et al (2007) The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120:1239–1247

    Article  PubMed  CAS  Google Scholar 

  32. Kim MA, Lee HS, Lee HE et al (2008) EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52:738–746

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors want to thank P. Duvillard and F. Drusch for their efficient help in this study

Conflicts of interest statement

We declare that we have no conflicts of interest.

Author information

Authors and Affiliations

  1. Research Translational Laboratory, Histocytopathology Unit, Institute Gustave Roussy, 39, rue Camille Desmoulins, 94805, Villejuif, France

    C. Uzan, A. Valent & P. Vielh

  2. Obstetrics and Gynecology Department, Tenon Hospital, 75020, Paris, France

    E. Darai, A. Cortez & R. Rouzier

  3. Obstetrics and Gynecology Department, Institute Alix de Champagne, 51092, Reims, France

    O. Graesslin

Authors
  1. C. Uzan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Darai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Valent
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O. Graesslin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Cortez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Rouzier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Vielh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Uzan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uzan, C., Darai, E., Valent, A. et al. Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch 454, 525–529 (2009). https://doi.org/10.1007/s00428-009-0755-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-009-0755-5

Keywords

Search

Navigation